Stocks › ADMA
ADMA BIOLOGICS, INC.
ADMA·Nasdaq·
United States·USD
United States·USD$10.18
+0.07 (+0.69%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ADMA
ADMA BIOLOGICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ADMAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ADMA by members of U.S. Congress · 0 on record
No congressional trades in ADMA on record.
Whale Activity
Position changes in ADMA reported for 2026-06-30 by 12 tracked institutional filers
- Increased3
- New0
- Held0
- Decreased7
- Closed0
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 38.4M | $321.0M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.1M | $84.6M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 10.1M | $84.4M | increased |
| D. E. Shaw & Co., Inc. | 5.3M | $44.1M | increased |
| Nantahala Capital Management, LLC | 2.4M | $19.8M | — |
| TWO SIGMA INVESTMENTS, LP | 2.0M | $16.9M | decreased |
| CITADEL ADVISORS LLC | 1.4M | $11.5M | decreased |
| MILLENNIUM MANAGEMENT LLC | 1.2M | $9.7M | decreased |
| Stonepine Capital Management, LLC | 740.0K | $6.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | 652.5K | $5.5M | decreased |
| Point72 Asset Management, L.P. | 413.9K | $3.5M | decreased |
| Bridgewater Associates, LP | 401.1K | $3.4M | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ADMA insiders, by quarter · Form 4
Recent Insider Transactions
404 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Grossman Jerrold BDirector | Purchase | +6,400 | $7.91 | $51K | May 27, 2026 | Form 4 ↗ |
| Grossman Jerrold BDirector | Purchase | +12.5K | $8.01 | $100K | May 12, 2026 | Form 4 ↗ |
| Grossman Jerrold BDirector | Purchase | +12.5K | $8.01 | $100K | May 11, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Tax withholding | −20.4K | $9.11 | $185K | Apr 1, 2026 | Form 4 ↗ |
| Guiheen Lawrence P.Director | Gift | +30.0K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| Guiheen Lawrence P.Director | Gift | −30.0K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| Grossman Adam SPresident and CEO · Director | Sale | −6,000 | $15.16 | $91K | Mar 16, 2026 | Form 4 ↗ |
| Grossman Adam SPresident and CEO · Director | Sale | −15.0K | $15.16 | $227K | Mar 16, 2026 | Form 4 ↗ |
| Grossman Adam SPresident and CEO · Director | Option exercise | +15.0K | $5.40 | $81K | Mar 16, 2026 | Form 4 ↗ |
| Guiheen Lawrence P.Director | Option exercise | +30.0K | $3.66 | $110K | Mar 13, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Sale | −10.1K | $15.63 | $158K | Mar 9, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Option exercise | +2,175 | $1.55 | $3K | Mar 9, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Option exercise | +1,525 | $2.35 | $4K | Mar 9, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Option exercise | +2,646 | $2.83 | $7K | Mar 9, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Option exercise | +1,250 | $4.31 | $5K | Mar 9, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Option exercise | +2,500 | $5.00 | $13K | Mar 9, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Other | −91.3K | $0.00 | $0 | Mar 9, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Tax withholding | −4,235 | $15.39 | $65K | Mar 7, 2026 | Form 4 ↗ |
| Grossman Adam SPresident and CEO · Director | Tax withholding | −29.5K | $15.39 | $454K | Mar 7, 2026 | Form 4 ↗ |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Tax withholding | −10.1K | $15.39 | $155K | Mar 6, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ADMA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 14.0M | $116.9M | 0.11% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 8.5M | $71.3M | 0.08% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 7.8M | $65.5M | 2.33% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 7.8M | $65.2M | 0.61% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 7.0M | $58.8M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 6.0M | $50.1M | 0.06% | Jun 30, 2026 |
| Small Cap Growth Fund American Century Mutual Funds, Inc. | 3.4M | $34.5M | 0.68% | Apr 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.7M | $22.3M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 2.5M | $21.3M | 0.06% | Jul 31, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.5M | $21.1M | 0.01% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ADMA's shares (CUSIP 000899104), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming adma biologics as client
- AMERICAN DEFENSE INTERNATIONALADMA BIOLOGICS, INC. · 2026 Q2 · HCR$10K
Filing ↗ - AMERICAN DEFENSE INTERNATIONALADMA BIOLOGICS, INC. · 2026 Q1 · HCR—
Filing ↗ - AMERICAN DEFENSE INTERNATIONAL, INC.ADMA BIOLOGICS, INC. · 2025 Q4 · HCR—
Filing ↗ - AMERICAN DEFENSE INTERNATIONAL, INC.ADMA BIOLOGICS, INC. · 2025 Q3 · HCR$10K
Filing ↗ - AMERICAN DEFENSE INTERNATIONAL, INC.ADMA BIOLOGICS, INC. · 2025 Q2—
Filing ↗
Government Contracts
Federal awards to ADMA BIOLOGICS, INC. · USAspending
No federal contract awards found for ADMA BIOLOGICS, INC..
U.S. Patents
Recent USPTO applications naming ADMA BIOLOGICS, INC.
No USPTO patent applications found for ADMA BIOLOGICS, INC..
Annual Financials
From ADMA's 10-K filings · XBRL
No annual XBRL figures on record for ADMA. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in ADMA's price history.
About ADMA BIOLOGICS, INC.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersRAMSEY, NJ
IncorporatedDE
SEC CIK0001368514 ↗
Former namesR&R ACQUISITION VI, INC